¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѽɺÎÀüÇÐȸ Á¦43Â÷ Ãß°è Çмú´ëȸ(Heart Failure Seoul 2021) 3ÀÏÂ÷ : 2021-09-18

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

´ëÇѽɺÎÀüÇÐȸ Á¦43Â÷ Ãß°è Çмú´ëȸ(Heart Failure Seoul 2021) 3ÀÏÂ÷ : 2021-09-18
±³À°ÀÏÀÚ : 2021-09-18
±³À°Àå¼Ò : ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5Ãþ ±×·£µåº¼·ë  
±³À°ÁÖÁ¦ : ´ëÇѽɺÎÀüÇÐȸ Á¦43Â÷ Ãß°è Çмú´ëȸ(Heart Failure Seoul 2021) 3ÀÏÂ÷
ÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѽɺÎÀüÇÐȸ  
´ã´çÀÚ : ¹éÁöÀº
¿¬¶ôó : 02-3275-5335  
À̸ÞÀÏ : kshf4@kshf.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 400¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 70,000¿ø      
ºñ°í ±³¼ö: 70,000¿ø, ÀϹÝÀÇ: 30,000¿ø, Àü°øÀÇ, °£È£»ç, 65¼¼ ÀÌ»ó, Çлý, ±âŸ(ÀÌ¿Ü ÀÇ·áÁ¾»çÀÚ): ¹«·á      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 10:00~10:30 Optimal HFrEF Treatment, New Perspectives  James Januzzi(Harvard University USA) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 10:30~11:00 Role of SGLT2I from Chronic to Acute HF, Where Is Proper Position in GDMT?  Michael Bohm(Saarland University Germany) 
Åä·Ð 09-18 ±×·£µåº¼·ë 11:00~11:20 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
È޽Ġ09-18 ±×·£µåº¼·ë 11:20~11:30 Break Time  () 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 11:30~11:45 Smartphone Application for Cardiac Rehabilitation: Strength and Weakness  ±èÀÀÁÖ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 11:45~12:00 Skeletal Muscle and Prognosis of HF: Can Cardiac Rehabilitation Overcome Muscle Wasting?  Kazunori Shimada(Juntendo University Hospital Japan) 
Åä·Ð 09-18 ±×·£µåº¼·ë 12:00~12:10 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
½Ä»ç 09-18 ±×·£µåº¼·ë 12:10~13:00 Lunch  () 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 13:00~13:50 Brigntening Abstract Presentation (II)  () 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 13:50~14:10 Challenge of Prescribing Inertia: from CHAMP-HF Registry  Biykem Bozkurt(Baylor College of Medicine HoustonTX) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 14:10~14:25 Performance Measures for HF Management in Korea  À±Á¾Âù(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 14:25~14:45 Benefits of Quadruple Therapy for HFrEF  JoAnn Lindenfeld(Vanderbilt University Medical Center Nashville TN) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 14:45~15:00 Comprehensive or Stepwise Treatment for HFrEF  ÃÖÁ¤Çö(ºÎ»êÀÇ´ë) 
Åä·Ð 09-18 ±×·£µåº¼·ë 15:00~15:20 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
È޽Ġ09-18 ±×·£µåº¼·ë 15:20~15:30 Break Time  () 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 15:20~15:35 Benefit of SGLT2 Inhibitors across the Cardiorenal Continuum  ±ÇÇõ»ó(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 15:35~15:50 Mechanistic Background of the Benefit of SGLT2 Inhibitors: Non-cardiac effect  ÃÖ¼ºÈñ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 15:50~16:05 Mechanistic Background of the Benefit of SGLT2 Inhibitors: Cardiac Effect  Á¶Àͼº(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 16:05~16:20 Positioning of SGLT2 Inhibitors in HF Management: How Should We Sequence?  John McMurray(Univ of Glasgow. UK) 
Åä·Ð 09-18 ±×·£µåº¼·ë 16:20~16:50 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
È޽Ġ09-18 ±×·£µåº¼·ë 16:50~17:00 Break Time  () 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 17:00~17:15 Ischemic Cardiomyopathy  Yuhui Zhang(CHFA China) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 17:15~17:30 Idiopathic Dilated Cardiomyopathy  ÀÌ»ó¾ð(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 17:30~17:45 Acute and Chronic Myocarditis  Jian Zhang(CHFA China) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 17:45~18:00 Hypertrophic Cardiomyopathy  ±èÀÎö(°è¸íÀÇ´ë) 
Åä·Ð 09-18 ±×·£µåº¼·ë 18:00~18:30 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó)  

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѽɺÎÀüÇÐȸ Á¦43Â÷ Ãß°è Çмú´ëȸ(Heart Failure Seoul 2021) 3ÀÏÂ÷ : 2021-09-18""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ (¿Â¶óÀÎ) Á¦58Â÷ ¾Ë·¹¸£±â ±³À°°­Á : 2021-09-25
´ÙÀ½±Û ´ëÇѽɺÎÀüÇÐȸ Á¦43Â÷ Ãß°è Çмú´ëȸ(Heart Failure Seoul 2021) 2ÀÏÂ÷ : 2021-09-17
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20668 ºÎ»ê ±¸Á¶½ÉÁúȯ¿¬±¸È¸ The 7th K-SCI(Korea Structural Cardiovascular Intervention) Symposium : 2024-06-01 0 46 2024-05-10
20667 ±¤ÁÖ ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ 2024³â ÇÁ·ÎÆ÷Æú ÁøÁ¤±³À° : 2024-06-01 0 34 2024-05-10
20666 ´ëÀü 2024³â ´ëÇÑ°¡Á¤ÀÇÇÐȸ ´ëÀü¼¼Á¾Áöȸ Ãá°èÇмú´ëȸ(°íÇ÷¾Ð, °ú¹Î¼º ÀåÁõÈıº, ¼ö¸éÀå¾Ö) : 2024-05-30 0 44 2024-05-10
20665 °æ±â ÇѸ²´ëÇб³¼º½Éº´¿ø ºñ´¢ÀÇÇаú ¿¬¼ö°­Á : 2024-05-30 0 111 2024-05-10
20664 ¼­¿ï °­³²¼¼ºê¶õ½ºº´¿ø (¿Â¶óÀÎ)¼Ò¾Æû¼Ò³â°ú Çù·ÂÀÇ»ç Áý´ãȸ : 2024-05-28 0 43 2024-05-10
20663 ºÎ»ê ´ëÇѳ»°úÀÇ»çȸ Á¦1ȸ ÃÊÀ½ÆÄ ½ÇÀü ¾ÆÄ«µ¥¹Ì : 2024-05-27 0 61 2024-05-10
20662 ¼­¿ï ´ëÇѿ°èÁٱ⼼Æ÷Àç»ýÀÇÇÐȸ - Á¦20ȸ Ãá°èÇмú´ëȸ (ÇÏÀ̺긮µå) : 2024-05-26 0 41 2024-05-10
20661 ºÎ»ê ´ëÇÑ°áÇÙ ¹× È£Èí±âÇÐȸ ºÎ¿ï°æÁöȸ 5¿ù ¿¬¼ö°­Á : 2024-05-26 0 71 2024-05-10
20660 ¼­¿ï ´ëÇѽŰæ±Ù°ñ°áÃÊÀ½ÆÄÇÐȸ Á¦1ȸ ÇÚÁî¿Â ¿öÅ©¼ó : 2024-05-25 0 38 2024-05-10
20659 ´ëÀü ´ëÇÑÀ̺ñÀÎÈÄ°úÀÇ»çȸ 2024 Áöȸ½ÉÆ÷Áö¾ö-´ëÀüÃæ³² : 2024-05-25 0 37 2024-05-10
20658 ºÎ»ê ´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ Á¦32Â÷ Á¤±âÇмú´ëȸ(2ÀÏÂ÷) : 2024-05-25 0 25 2024-05-10
20657 ´ë±¸ Ä¥°î°æºÏ´ëÇб³º´¿ø The 1st International Symposium on Precision Oncology in Breast Cancer : 2024-05-25 0 34 2024-05-10
20656 ¼­¿ï (¿Â¶óÀÎ)2024³â ´ëÇÑ°ñ´ë»çÇÐȸ Á¦1Â÷ FLS ÄÚµð³×ÀÌÅÍ ¿öÅ©¼ó : 2024-05-24 0 28 2024-05-10
20655 ¼­¿ï Á¦ 66ȸ Çѱ¹Ç×°ø¿ìÁÖÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-24 0 47 2024-05-10
20654 ´ëÀü °ø°ø±â°ü ÀçÁ÷ÀÇ»ç Ãá°è Çмú´ëȸ (2ÀÏÂ÷) : 2024-05-24 0 32 2024-05-10
21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷